Hydrogen Sulfide SIBO Symptoms

Hydrogen Sulfide SIBO Symptoms: A Comprehensive Evidence-Based Guide

Introduction

Small intestinal bacterial overgrowth (SIBO) is a complex digestive condition characterised by an excessive number of bacteria in the small intestine. While many people are familiar with hydrogen and methane-dominant SIBO, hydrogen sulfide (H₂S) SIBO represents a distinct subtype that is increasingly recognised in clinical practice. This comprehensive guide explores hydrogen sulfide SIBO symptoms, diagnosis, and management based on current scientific research.

What is Hydrogen Sulfide SIBO?

Hydrogen sulfide SIBO occurs when sulfate-reducing bacteria proliferate in the small intestine, producing excessive amounts of hydrogen sulfide gas. Research has identified specific bacterial species, particularly Desulfovibrio and Fusobacterium, as key hydrogen sulfide producers in the gastrointestinal tract. These bacteria convert sulfate compounds into hydrogen sulfide through a process called dissimilatory sulfate reduction.

Like hydrogen and methane-producing organisms, sulfate-reducing bacteria create a toxic gas (when in excess) that can have significant effects on intestinal health and function. Studies have shown that breath hydrogen sulfide levels are distinctly altered in a sub-set of patients with SIBO, particularly those with diarrhoea-predominant irritable bowel syndrome (IBS-D).

Primary Hydrogen Sulfide SIBO Symptoms

Gastrointestinal Symptoms

Research has documented several characteristic symptoms associated with hydrogen sulfide SIBO:

Diarrhoea: Multiple studies have established a strong connection between elevated breath hydrogen sulfide levels and diarrhoea-predominant symptoms. Patients with IBS-D demonstrate higher breath H₂S levels that correlate with increased abundance of hydrogen sulfide-producing bacteria, including Fusobacterium and Desulfovibrio species.

Chronic Bloating and Distention: Abdominal bloating is one of the most common complaints in SIBO patients. The accumulation of hydrogen sulfide gas in the intestinal tract contributes to uncomfortable bloating that typically worsens after meals and throughout the day. Clinical studies have found that patients with SIBO commonly report bloating as a predominant symptom, with prevalence rates ranging from 43% to higher in various patient populations.

Abdominal Pain: Research indicates that abdominal pain is a frequent manifestation of SIBO. Studies have shown correlations between microbial metabolic pathways for hydrogen sulfide production and symptom severity, particularly abdominal discomfort. The toxic effects of hydrogen sulfide on the intestinal epithelium may contribute to pain and cramping.

Gas and Flatulence: Excessive gas production is characteristic of hydrogen sulfide SIBO. Hydrogen sulfide is recognised as one of the main malodorous compounds in human flatus, and its overproduction can lead to embarrassing and uncomfortable symptoms. Studies have reported flatulence in approximately 17% of patients with SIBO-related symptoms.

Associated Systemic Symptoms

Beyond gastrointestinal manifestations, hydrogen sulfide SIBO can produce systemic effects:

Nausea and Vomiting: Clinical studies have documented that patients with SIBO, particularly those who have undergone certain surgical procedures, more commonly report nausea and vomiting compared to those without bacterial overgrowth.

Malabsorption and Nutritional Deficiencies: SIBO can predispose individuals to various nutritional deficiencies. Research has identified specific patterns of deficiency associated with different SIBO subtypes. Studies have found correlations with low serum vitamin D, low serum ferritin (iron deficiency), and altered vitamin B12 metabolism in patients with SIBO. The relationship between hydrogen sulfide abundance and vitamin B12 intake has been documented in scientific literature.

Intestinal Permeability: Research has demonstrated that excessive hydrogen sulfide, along with other bacterial metabolites such as lipopolysaccharides and methane, can disrupt epithelial integrity and contribute to increased intestinal permeability, often referred to as “leaky gut.” This barrier dysfunction allows harmful substances to enter the bloodstream and trigger systemic inflammation.

Facial Erythema and Skin Manifestations: Emerging research has revealed a connection between SIBO and facial redness. A recent clinical study found that patients with hydrogen sulfide-dominant SIBO experienced significant reductions in facial erythema following treatment, demonstrating a gut-skin axis connection.

Discover the reasons for your gut symptoms.

View our gut health tests

Understanding the Underlying Mechanisms

Bacterial Species Involved

Scientific research has identified specific bacterial populations responsible for hydrogen sulfide production:

• Desulfovibrio species: These sulfate-reducing bacteria are primary hydrogen sulfide producers in the intestinal microbiota. Studies have shown that Desulfovibrio piger is particularly associated with hydrogen sulfide production and has been linked to inflammatory bowel disease development.
• Fusobacterium species: Research has documented higher relative abundance of Fusobacterium in patients with elevated breath hydrogen sulfide levels and diarrhea-predominant symptoms.
• Enterobacteriaceae: Studies have found higher abundance of Enterobacteriaceae, including Escherichia and Klebsiella species, in patients with SIBO, with correlations to symptom severity including abdominal pain, diarrhea, and bloating.

Microbial Metabolic Pathways

Advanced metagenomic analysis has revealed that microbial metabolic pathways for carbohydrate fermentation, hydrogen production, and hydrogen sulfide production are enhanced in SIBO patients. These pathways involve:

• Sulfate reduction pathways that convert sulfate into hydrogen sulfide
• Metabolism of sulfur-containing compounds from the diet
• Production of hydrogen gas that can be further metabolised by sulfate-reducing bacteria

Effects on Gut Health

Hydrogen sulfide has complex and sometimes contradictory effects on intestinal health:

• Epithelial Damage: Excess hydrogen sulfide can damage the intestinal lining, contributing to increased permeability and inflammation. Research has implicated this toxic gas in the pathogenesis of ulcerative colitis and other inflammatory conditions.
• Microbiome Disruption: Studies have demonstrated that SIBO patients show significantly decreased microbial diversity and network disruption, with progressive changes associated with increasing bacterial overgrowth severity.
• Inflammatory Response: The accumulation of hydrogen sulfide in the bowel has been linked to chronic inflammation and may be involved in both too-low and too-high levels driving inflammation—suggesting a balanced level is needed for intestinal health.

Testing For Hydrogen Sulfide SIBO

Breath Testing

Hydrogen sulfide breath testing (not available in the U.K currently) has emerged as a potential diagnostic tool for hydrogen sulfide SIBO.

Testing Protocol: Studies have evaluated the diagnostic value of hydrogen sulfide breath tests using lactulose as a substrate. Breath samples are collected at baseline and at intervals (typically every 15-30 minutes) for up to 2-3 hours after substrate ingestion.

Diagnostic Criteria: Research has established that breath hydrogen sulfide levels ≥62.5 ppb (parts per billion) at 90 minutes, or an increase of ≥25.0 ppb from baseline, may indicate positive results. Studies report sensitivity of 66.4%, specificity of 79.1%, and accuracy of 73.3% for hydrogen sulfide breath testing.

Correlation with Other Gases: Scientific evidence shows that hydrogen sulfide levels at 90 minutes are positively correlated with both hydrogen and methane levels, indicating that mixed gas patterns are common.

Microbiome testing: It’s important to highlight that, from a symptom perspective, the bacterial overgrowth may reside with in the large intestine, making stool testing highly beneficial. Our Ultimate Gut Health Test assesses for hydrogen sulfide producing organisms in the large intestine, as well as methane producing organisms.

Other Diagnostic Considerations

While breath testing is non-invasive, other diagnostic approaches include:

• Small Bowel Aspirate Culture: The gold standard, with ≥10³ colony-forming units per mL considered positive
• Clinical Symptom Assessment: Comprehensive evaluation of gastrointestinal symptoms

Risk Factors for Hydrogen Sulfide SIBO

Research has identified several conditions that may predispose individuals to SIBO:

• Proton Pump Inhibitor (PPI) Use: Long-term PPI treatment has been associated with increased SIBO incidence, with studies reporting positive breath tests in 26% of patients after 6 months of therapy. PPIs reduce gastric acid, which normally helps control bacterial populations.
• Gastrointestinal Structural or Neurological Disorders: Studies show higher pre-test probability in patients with structural or neurological GI conditions.
• Gastroparesis: Research indicates SIBO is very common in patients with gastroparesis, with 60% showing positive breath tests and a particular predominance of abdominal pain and bloating symptoms.
• Previous Abdominal Surgery: Particularly procedures like Roux-en-Y gastric bypass, which show 73.4% SIBO prevalence in some studies.
• Dietary Factors: Low fiber intake has been correlated with certain SIBO subtypes, and dietary patterns influence bacterial populations and gas production. High protein or/and fat diets may also contribute to imbalances in hydrogen sulfide production for some, especially when fibre is low.

Treatment Approaches

Antimicrobial Therapy

Rifaximin: While research shows rifaximin is effective for hydrogen-positive SIBO (47.4% response rate for hydrogen alone, 80% for hydrogen and methane combined), its effectiveness for hydrogen sulfide-dominant SIBO requires further study.

Botanical Antimicrobials: Recent research has demonstrated promising results with botanical supplemental regimens. One open-label clinical study found that botanical supplements led to negative breath test results at week 10 in 66.7% of participants with hydrogen sulfide-dominant SIBO—the highest response rate among all SIBO subtypes tested.

Hydrogen Sulfide-Specific Interventions

Bismuth Subsalicylate: Research has shown that bismuth subsalicylate can dramatically reduce hydrogen sulfide release in the colon. Studies demonstrate a dose-dependent relationship, with fecal homogenates showing decreased H₂S production when exposed to bismuth compounds that bind hydrogen sulfide.

Molybdenum and vitamin B6: Molybdenum plays a crucial role in addressing hydrogen sulfide (H2S) SIBO by supporting the body’s natural detoxification of sulfur compounds. This trace mineral is an essential cofactor for sulfite oxidase, an enzyme that converts potentially toxic sulfites into safer sulfates that can be readily excreted. Vi tamin B6 is a cofactor for several enzymes involved in sulfur metabolism which help regulate the transsulfuration pathway. This pathway is important for processing sulfur-containing amino acids like cysteine and methionine.

Butyrate: Butyrate, a metabolite produced by certain bacteria, can be helpful in modulating the microbioe and has an antagonistic relationship with hydrogen sulfide. Hydrogen sulfide can inhibit colons ability to oxidise (use) butyrate leading to cellular energy deficiency, inflammation, and diseases like ulcerative colitis.

Dietary Modifications

While not extensively studied specifically for hydrogen sulfide SIBO, research suggests:

• Low-FODMAP Diet: May help reduce fermentable substrates for bacterial metabolism
• Sulfur-Containing Food Reduction: Though not explicitly proven, limiting dietary sulfate sources may be beneficial
• Fiber Optimisation: Studies show correlations between fiber intake and different SIBO subtypes. This needs to be personalised to the individual.

Probiotic and Prebiotic Approaches

Research has documented beneficial shifts in gut microbiome composition with certain treatments:

• Increases in short-chain fatty acid-producing bacteria (Akkermansia muciniphila, Faecalibacterium prausnitzii)
• Decreases in the Firmicutes/Bacteroidetes ratio
• Improved microbial diversity

Probiotics should be chosen for specific purposes and I am not aware of any good research demonstrating that we can select any specific strain of probiotic to combat hydrogen sulfide. Having said that, Lactobacillus species have shown potential to significantly reduce the Desulfovibrio genus (that are hydrogen sulfide producers) in human studies. Interestingly, hydrogen sulfide is toxic to lactobacillus bacteria and so you commonly see lower levels of them when someone has excessive hydrogen sulfide production.

Addressing Intestinal Permeability

Studies have shown that successful SIBO treatment can modulate markers of intestinal barrier function, including:

• Zonulin (a marker of tight junction regulation)
• Diamine oxidase (DAO)
• Histamine levels
• Lipopolysaccharide (LPS) binding antibodies

To support the gut lining a great product is Rezcue which contains both zinc carnosine and l-glutamine, the two most evidenced nutrients for leaky gut.

Monitoring and Follow-Up

Research supports the use of repeat breath testing to:

• Track treatment response
• Monitor for recurrence
• Guide therapeutic decisions

The Gut-Systemic Connection

Emerging research highlights important connections between hydrogen sulfide SIBO and systemic health:

Gut-Skin Axis: Clinical studies have documented significant improvements in facial erythema with SIBO treatment, with reductions observed across all SIBO subtypes, including hydrogen sulfide-dominant cases.

Neuropsychological Symptoms: While requiring more research, gut microbiome dysbiosis in SIBO may be associated with neuropsychological symptoms through the gut-brain axis.

Autoimmunity and Chronic Inflammation: The increased intestinal permeability associated with hydrogen sulfide and other bacterial metabolites has been linked to chronic diseases, autoimmune disorders, and systemic inflammatory conditions.

Conclusion

Hydrogen sulfide SIBO represents a distinct subtype of small intestinal bacterial overgrowth with characteristic symptoms including diarrhea, bloating, abdominal pain, and potentially constipation. The condition is driven by sulfate-reducing bacteria, particularly Desulfovibrio and Fusobacterium species, which produce toxic hydrogen sulfide gas that affects intestinal health and function.

Diagnosis has advanced with the development of hydrogen sulfide breath testing, which shows promise in detecting cases missed by traditional hydrogen breath tests. Treatment approaches are evolving, with botanical antimicrobials showing particular promise for this subtype, and bismuth subsalicylate offering a hydrogen sulfide-specific intervention.

The systemic effects of hydrogen sulfide SIBO extend beyond the gastrointestinal tract, affecting nutritional status, skin health, and intestinal barrier function. Understanding this SIBO subtype allows for more targeted diagnostic and therapeutic approaches, potentially improving outcomes for patients with previously difficult-to-explain digestive symptoms.

If you suspect you may have hydrogen sulfide SIBO based on the symptoms described in this article, consult with a healthcare provider experienced in SIBO diagnosis and management. Proper testing and individualised treatment plans are essential for addressing this complex condition effectively.

References

1. Gillevet PM, Forsyth C, Keshavarzian A. Hydrogen sulphide in exhaled breath: a potential biomarker for small intestinal bacterial overgrowth in IBS. Journal of Breath Research. 2016;10(2):026011. PMID: 27163246
2. Liu CY, Zhang S, Yang MX, Tang W. [The diagnostic value of hydrogen sulfide breath test for small intestinal bacterial overgrowth]. Zhonghua Nei Ke Za Zhi. 2021;60(4):311-315. PMID: 33765706
3. Shah R, Chung S, Chaudhari R, et al. An Oral Botanical Supplement Improves Small Intestinal Bacterial Overgrowth (SIBO) and Facial Redness: Results of an Open-Label Clinical Study. Nutrients. 2024;16(18):3147. PMID: 39339748
4. Takakura W, Pimentel M. Small Intestinal Bacterial Overgrowth and Irritable Bowel Syndrome – An Update. Frontiers in Psychiatry. 2020;11:664. PMID: 32754068
5. Singh VV, Toskes PP. Preferential usage of rifaximin for the treatment of hydrogen-positive small intestinal bacterial overgrowth. Expert Review of Gastroenterology & Hepatology. 2019;13(8):731-733. PMID: 31333225
6. Suarez F, Furne J, Springfield J, Levitt M. Bismuth subsalicylate markedly decreases hydrogen sulfide release in the human colon. Gastroenterology. 1998;114(5):923-929. PMID: 9558280
7. Mego M, Accarino A, Malagelada JR, Guarner F, Azpiroz F. Identification of SIBO Subtypes along with Nutritional Status and Diet as Key Elements of SIBO Therapy. Nutrients. 2024;16(13):2139. PMID: 39000446
8. Wolf PG, Parthasarathy G, Chen J, et al. Methanogens and Hydrogen Sulfide Producing Bacteria Guide Distinct Gut Microbe Profiles and Irritable Bowel Syndrome Subtypes. Cellular and Molecular Gastroenterology and Hepatology. 2022;14(6):1523-1533. PMID: 36114762
9. Rao SS, Bhagatwala J. Small intestinal bacterial overgrowth: clinical features and therapeutic management. Clinical and Translational Gastroenterology. 2019;10(10):e00078. PMID: 31584459
10. Pimentel M, Saad RJ, Long MD, Rao SSC. ACG Clinical Guideline: Small Intestinal Bacterial Overgrowth. American Journal of Gastroenterology. 2020;115(2):165-178. PMID: 32023228
11. Rezaie A, Buresi M, Lembo A, et al. Hydrogen and Methane-Based Breath Testing in Gastrointestinal Disorders: The North American Consensus. American Journal of Gastroenterology. 2017;112(5):775-784. PMID: 28323273
12. Lau L, Luk A, Wang C, et al. Understanding Our Tests: Hydrogen-Methane Breath Testing to Diagnose Small Intestinal Bacterial Overgrowth. Digestive Diseases and Sciences. 2023;68(4):1139-1148. PMID: 36744854
13. Kushkevych I, Dordević D, Vítězová M. Toxicity of hydrogen sulfide toward sulfate-reducing bacteria Desulfovibrio piger Vib-7. Archives of Microbiology. 2019;201(3):389-397. PMID: 30707247
14. Kushkevych I, Kotrsová V, Dordević D, et al. Hydrogen Sulfide as a Toxic Product in the Small-Large Intestine Axis and its Role in IBD Development. Journal of Clinical Medicine. 2019;8(7):1054. PMID: 31330956
15. de Clercq NC, Groen AK, Romijn JA, Nieuwdorp M. Role of Hydrogen Sulfide in Inflammatory Bowel Disease. Antioxidants. 2023;12(8):1570. PMID: 37627565
16. Saffouri GB, Shields-Cutler RR, Chen J, et al. Small intestinal microbial dysbiosis underlies symptoms associated with functional gastrointestinal disorders. Nature Communications. 2019;10(1):2012. PMID: 31040281
17. Sanaei Dashti A, Rao S. Bacterial overgrowth and lactose intolerance: how to best assess. Current Opinion in Clinical Nutrition and Metabolic Care. 2022;25(5):328-333. PMID: 35838278
18. Compare D, Pica L, Rocco A, et al. Effects of long-term PPI treatment on producing bowel symptoms and SIBO. European Journal of Clinical Investigation. 2011;41(4):380-386. PMID: 21128930
19. Erdogan A, Rao SS, Gulley D, Jacobs C, Lee YY, Badger C. Small intestinal bacterial overgrowth: duodenal aspiration vs glucose breath test. Neurogastroenterology & Motility. 2015;27(4):481-489. PMID: 25600077
20. Jacobs C, Coss Adame E, Attaluri A, Valestin J, Rao SS. Dysmotility and proton pump inhibitor use are independent risk factors for small intestinal bacterial and/or fungal overgrowth. Alimentary Pharmacology & Therapeutics. 2013;37(11):1103-1111. PMID: 23574267
21. Ratuapli SK, Ellington TG, O’Neill MT, et al. Proton pump inhibitor therapy use does not predispose to small intestinal bacterial overgrowth. American Journal of Gastroenterology. 2012;107(5):730-735. PMID: 22334250
22. Losurdo G, Leandro G, Ierardi E, et al. Small Intestinal Bacterial Overgrowth and Irritable Bowel Syndrome-Related Symptoms: Experience with Rifaximin. World Journal of Gastroenterology. 2016;22(28):6571-6577. PMID: 27605889
23. Ghoshal UC, Shukla R, Ghoshal U. Small Intestinal Bacterial Overgrowth and Irritable Bowel Syndrome: A Bridge between Functional Organic Dichotomy. Gut and Liver. 2017;11(2):196-208. PMID: 28274108
24. Adike A, DiBaise JK. Small Intestinal Bacterial Overgrowth: Nutritional Implications, Diagnosis, and Management. Gastroenterology Clinics of North America. 2018;47(1):193-208. PMID: 29413012
25. Bohm M, Siwiec RM, Wo JM. Diagnosis and management of small intestinal bacterial overgrowth. Nutrition in Clinical Practice. 2013;28(3):289-299. PMID: 23614962
26. Shah A, Talley NJ, Jones M, et al. Small intestinal bacterial overgrowth in irritable bowel syndrome: a systematic review and meta-analysis of case-control studies. American Journal of Gastroenterology. 2020;115(2):190-201. PMID: 31764427
27. Quigley EMM, Murray JA, Pimentel M. AGA Clinical Practice Update on Small Intestinal Bacterial Overgrowth: Expert Review. Gastroenterology. 2020;159(4):1526-1532. PMID: 32763404
28. Banaszak M, Górna I, Woźniak D, Przysławski J, Drzymała-Czyż S. Association between Gut Dysbiosis and the Occurrence of SIBO, LIBO, SIFO and IMO. Microorganisms. 2023;11(3):573. PMID: 36985152
29. Achufusi TGO, Sharma A, Zamora EA, Manocha D. Small Intestinal Bacterial Overgrowth: Comprehensive Review of Diagnosis, Prevention, and Treatment Methods. Cureus. 2020;12(6):e8860. PMID: 32656109
30. Ghannoum M, Demeester J, Najjar D, et al. Small Intestinal Bacterial and Fungal Overgrowth: Health Implications and Management Perspectives. Nutrients. 2025;17(8):1317. PMID: 40284229